Neurim collaborated with Azrieli National Center for Autism and Neurodevelopment Research to assess the burden of Insomnia in children with autism

In September 2021, Neurim entered into research collaboration with the Azrieli National Center for Autism and Neurodevelopment Research.
The aim of the collaboration was to promote better understanding of insomnia in children with Autism Spectrum Disorder and its burden.

A retrospective cross-sectional study was conducted by the Azrieli National Center for Autism and Neurodevelopment Research, using the national autism database of Israel.
Health services utilization including child health, and medication use were compared among children who have insomnia vs. children who don’t.
The surprising results revealed significantly higher utilization of health services by children with ASD and insomnia than by their counterparts without insomnia, and indicates that treating sleeping problems in children with ASD may have a broad clinical and economic impact that extends beyond the expected improvement in the sleep quality of these children and their parents.

The results will be presented at the upcoming WSC 2022, Rome.

 

      


  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto is now available in Spain!
    • Neurim Pharmaceuticals is attending World Sleep Congress 2022, March 11-16, Rome, Italy
    • Neurim conducted a survey via Brandman Research, assessing the characteristics of insomnia in children with ASD and the distress it causes to the children and their families
  • Partners

    Partners